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Soluble vascular endothelial growth factor receptor-3 suppresses
lymphangiogenesis and lymphatic metastasis in bladder cancer
Abstract
Background: Most bladder cancer patients experience lymphatic metastasis in the course of disease
progression, yet the relationship between lymphangiogenesis and lymphatic metastasis is not well
known. The aim of this study is to elucidate underlying mechanisms of how expanded lymphatic vessels
and tumor microenvironment interacts each other and to find effective therapeutic options to inhibit
lymphatic metastasis. Results: The orthotopic urinary bladder cancer (OUBC) model was generated by
intravesical injection of MBT-2 cell lines. We investigated the angiogenesis, lymphangiogenesis, and
CD11b+/CD68+ tumor-associated macrophages (TAM) by using immunofluorescence staining. OUBC
displayed a profound lymphangiogenesis and massive infiltration of TAM in primary tumor and
lymphatic metastasis in lymph nodes. TAM flocked near lymphatic vessels and express higher levels of
VEGF-C/D than CD11b- cells. Because VEGFR-3 was highly expressed in lymphatic vascular
endothelial cells, TAM could assist lymphangiogenesis by paracrine manner in bladder tumor.
VEGFR-3 expressing adenovirus was administered to block VEGF-C/D signaling pathway and
clodronate liposome was used to deplete TAM. The blockade of VEGF-C/D with soluble VEGF
receptor-3 markedly inhibited lymphangiogenesis and lymphatic metastasis in OUBC. In addition, the
depletion of TAM with clodronate liposome exerted similar effects on OUBC. Conclusion: VEGF-C/D
are the main factors of lymphangiogenesis and lymphatic metastasis in bladder cancer. Moreover, TAM
plays an important role in these processes by producing VEGF-C/D. The inhibition of
lymphangiogenesis could provide another therapeutic target to inhibit lymphatic metastasis and
recurrence in patients with invasive bladder cancer.
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Abstract
Background: Most bladder cancer patients experience lymphatic metastasis in the course of disease progression,
yet the relationship between lymphangiogenesis and lymphatic metastasis is not well known. The aim of this study
is to elucidate underlying mechanisms of how expanded lymphatic vessels and tumor microenvironment interacts
each other and to find effective therapeutic options to inhibit lymphatic metastasis.
Results: The orthotopic urinary bladder cancer (OUBC) model was generated by intravesical injection of MBT-2 cell
lines. We investigated the angiogenesis, lymphangiogenesis, and CD11b+/CD68+ tumor-associated macrophages
(TAM) by using immunofluorescence staining. OUBC displayed a profound lymphangiogenesis and massive
infiltration of TAM in primary tumor and lymphatic metastasis in lymph nodes. TAM flocked near lymphatic vessels
and express higher levels of VEGF-C/D than CD11b- cells. Because VEGFR-3 was highly expressed in lymphatic
vascular endothelial cells, TAM could assist lymphangiogenesis by paracrine manner in bladder tumor. VEGFR-3
expressing adenovirus was administered to block VEGF-C/D signaling pathway and clodronate liposome was used
to deplete TAM. The blockade of VEGF-C/D with soluble VEGF receptor-3 markedly inhibited lymphangiogenesis
and lymphatic metastasis in OUBC. In addition, the depletion of TAM with clodronate liposome exerted similar
effects on OUBC.
Conclusion: VEGF-C/D are the main factors of lymphangiogenesis and lymphatic metastasis in bladder cancer.
Moreover, TAM plays an important role in these processes by producing VEGF-C/D. The inhibition of
lymphangiogenesis could provide another therapeutic target to inhibit lymphatic metastasis and recurrence in
patients with invasive bladder cancer.
Background
Bladder cancer ranks as the second most common geni-
tourinary cancer and is associated with frequent distant
metastasis at the time of both initial diagnosis and
recurrence [1,2]. Even though radical cystectomy and
lymph node dissection may be curative, about 50% of
patients with muscle-invasive bladder cancer eventually
experience recurrence and metastases within 2 years of
surgery, and most of them die of the disease [1]. In
patients with bladder cancer, the presence of metastasis
in regional lymph node is a strong indicator of high
recurrence (~55% at 5 years after cystectomy) and rela-
tively poor survival rate (~45% at 5 years after cystect-
omy) [3,4]. Intriguingly, patients and mice with bladder
cancer display profound lymphatic vessels in the periph-
eral and central regions, which could be actively
involved in lymphatic metastasis to lymph node [5,6].
However, the underlying causes and driving forces of
the expansion of lymphatic vessels in bladder cancer
and underlying mechanisms of how the expanded lym-
phatic vessels are involved in bladder cancer metastasis
to lymph nodes are poorly understood.
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New lymphatic vessel formation, lymphangiogenesis, is
potently induced by lymphangiogenic growth factors
such as vascular endothelial growth factor (VEGF)-C
and VEGF-D (VEGF-C/D) through binding and activa-
tion of their receptor tyrosine kinase, VEGF receptor-3
(VEGFR-3) [7,8]. Proliferation, sprouting, expansion,
enlargement and permeability of lymphatic vessels are
largely affected by VEGF-C/D, and these processes facil-
itate cancer cell migration into the lymphatic vessels
and spread to sentinel lymph node (SLN) [9-11].
Accordingly, blocking the VEGF-C/D-VEGFR-3 signal-
ing pathway suppresses tumor lymphangiogenesis and
lymph node metastasis in several tumor models [12-15].
These reports indicate that VEGF-C/D-mediated
VEGFR-3 activation contributes to not only lymphatic
vessel growth but also tumor cell dissemination via lym-
phatic vessels. In addition, VEGF-C/D is highly
expressed in patients with bladder cancer [16,17] and
this expression is closely related to lymph node metasta-
sis, but it has an inconsistent relationship with prognosis
and survival rate. Yet, causative relationship between
expression of VEGF-C/D, lymphangiogenesis and lymph
node metastasis in the bladder cancer is not exactly
known. It is known that CD11b+ tumor-associated
macrophages (TAM) mainly express genes of the M2
type such as CD68, F4/80 and VEGFR-1, and is actively
involved in tumor invasion and progression [18]. Accu-
mulating evidences indicate that TAM takes consider-
able part in promoting tumor angiogenesis and
progression by abundant secretions of diverse angio-
genic and lymphangiogenic growth factors [18-23].
However, involvement of TAM in lymphangiogenesis
and lymphatic metastasis to SLN is unknown in the
bladder cancer. Therefore, in this study, we investigated
roles of VEGF-C/D and involvement of TAM in tumor
lymphangiogenesis and lymphatic metastasis in the mur-
ine orthotopic urinary bladder cancer (OUBC) model.
We found that OUBC induces profound lymphangio-
genesis in the tumor and SLN and substantial lymphatic
metastasis to SLN through VEGF-C/D-VEGFR-3 signal-
ing pathway. Furthermore, CD11b+/CD68+ TAM was
largely infiltrated around the tumor lymphatic vessels,
and they were closely involved in the OUBC-induced
lymphangiogenesis and lymphatic metastasis, possibly
through secretary lymphangiogenic factors such as
VEGF-C/D. Our findings provide a novel insight and
useful treatment strategy how to control lymphatic
metastasis in the patients with bladder cancer through
suppression of VEGFR-3 signaling pathway.
Methods
Generation of OUBC mouse model
Eight-ten weeks old female C3H/HeN mice were pur-
chased from the Orient Bio Inc. (Seongnam, Korea).
Animal care and experimental procedures were per-
formed under approval from the Animal Care Commit-
tees of KAIST. The murine bladder cancer cell line
MBT-2 was originally obtained from Dr. Timothy Ratliff
(University of Iowa, Iowa City, Iowa). The cell line initi-
ally originated from a transplantable N-[4-(5-nitro-2-
furyl)-2-thiazolyl]-formamide-induced bladder tumor in
a C3H mouse [24]. The MBT-2 cells were cultured in
DMEM (Lonza, Walkersville, MD) containing 10% heat-
inactivated fetal bovine serum (Cambrex, Walkersville,
MD), 50 U/ml penicillin and 50 mg/ml streptomycin
(Invitrogen, Grand Island, NY) in plastic tissue culture
dishes at 37°C in a humidified atmosphere of 5% CO2.
The cells were trypsinized and resuspended to a single
cell suspension in PBS. The mice were anesthetized with
an intramuscular injection of ketamine (100 mg/kg) and
xylazine (10 mg/kg). A 24G catheter (Becton Dickinson
Korea Ltd., Korea) was inserted into the bladder through
the urethra. The bladder epithelial layer was wounded
with 100 μl of 0.1N HCl and NaOH to improve tumor
cell implantation. 1 × 106 suspended MBT-2 cells in
100 μl of PBS were injected into the bladder cavity.
Histologic and morphometric analysis
Four weeks after MBT-2 cell implantation, bladder and
SLN were sampled. For whole-mount staining, tissue
samples were fixed in 1% paraformadehyde in PBS for 1
hr at room temperature (RT). Whole-mounted tissues
were incubated for 3 hr at RT with hamster monoclonal
anti-platelet endothelial cell adhesion molecule-1
(PECAM-1) antibody 1:1,000 (Chemicon International,
Temecula, CA), or rabbit polyclonal anti-lymphatic ves-
sel endothelial hyaluronan receptor-1 (LYVE-1) antibody
1:1000 (Upstate, Lake Placid, NY) after a blocking the
fixed tissues with 5% donkey serum in PBST (0.3%
Triton X-100 in PBS) for 1 hr at RT. Samples were
incubated for 2 hrs at RT with HRP-conjugated anti-
hamster antibody 1:100 (Jackson ImmunoResearch,
West Grove, PA) or HRP-conjugated anti-rabbit anti-
body, 1:100 (Amersham, Piscataway, NJ) and developed
with 3,3’-diaminobenzidine (DAB) substrate kit accord-
ing to manufacturer’s instruction (Vector, Burlingame,
CA). Samples were analyzed and photographed with a
Zeiss Stemi SV6 stereomicroscope. For hematoxylin-
eosin (H&E) and immunofluorescent staining of tissue
sections, Samples were fixed in acetone for overnight at
-20°C. Samples were embedded in paraffin block after
serial incubation with methyl benzoate and xylene for
30 min at RT. Paraffin blocks were cut in 5-10 μm sec-
tions using Microm HM 335E rotary microtome (IMEB
Inc, San Marcos, CA). Tissue sections were blocked
with 5% goat or donkey serum in TBST (0.03% Triton
X-100 in TBS) after dissolving the paraffin with xylene
and acetone, immunostained with antibodies for 3 hr;
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these included hamster monoclonal anti-PECAM-1 anti-
body 1:200, rabbit polyclonal anti-LYVE-1 antibody
1:200, rat monoclonal anti-CD11b antibody 1:100 (BD
Pharmingen, Franklin Lakes, NJ), rat monoclonal FITC-
conjugated anti-CD11b antibody 1:50 (BD Pharmino-
gen), mouse monoclonal anti-Cytokeratin antibody
(Abcam Inc, Cambridge, MA), rat monoclonal FITC-
conjugated anti-CD68 antibody 1:100 (Serotec Ltd.,
Oxford, UK), rat monoclonal anti-F4/80 antibody 1:100
(Research Diagnostics Inc., Flanders, NJ), goat polyclonal
anti-VEGFR-3 antibody 1:100 (R&D Systems, Inc., Min-
neapolis, MN), goat polyclonal anti-VEGF-C antibody
1:100 (Santa Cruz Biotechnology, Inc.). After several
washing steps using TBS, FITC-conjugated anti-hamster
IgG antibody 1:1000, FITC-conjugated anti-rat IgG anti-
body 1:1000, FITC-conjugated anti-mouse IgG antibody
1:1000, Cy3-conjugated anti-rabbit IgG antibody 1:1000,
Cy3-conjugated anti-rat IgG antibody 1:1000, Rhoda-
mine-conjugated anti-goat IgG antibody 1:1000 were
used as secondary antibodies. All secondary antibodies
were purchased from Jackson ImmunoResearch Labora-
tories, Inc. Goat Fab fragment anti-mIgG (Jackson
ImmunoResearch Laboratories, Inc.) was used to block
endogenous mouse IgG to use mouse antibody on
mouse tissue. Fluorescent signals were visualized and
digital images were obtained using a Zeiss LSM 510
confocal microscope equipped with argon and helium-
neon lasers (Carl Zeiss, Germany) or using a Zeiss
ApoTome microscope coupled to a monochrome
charge-coupled device camera (AxioVision, Carl Zeiss).
Morphometric measurements of lymphatic and blood
vessels in tumor and SLN were made from immunos-
tained tissue sections by photographic analysis using
ImageJ software (http://rsb.info.nih.gov/ij) after convert-
ing the images into 8-bit gray scale. Measurements of
the number and size of the lymphatic vessels having
lumen in tumor section were made at a screen magnifi-
cation of 100×, each 0.84 mm2 in area. Measurements
of the densities of the blood vessels in tumor section
were made at a screen magnification of 100×, each 0.84
mm2 in area, whereas those and pan-cytokeratin stained
cancer cells in SLN were made in total sectioned area
(0.3-1.2 mm2), and 4 to 5 mice were used per group. To
exclude background fluorescence, only pixels over a cer-
tain level (>50 intensity value) were taken. Measure-
ments of the densities of the lymphatic vessels and
blood vessels in the whole mount staining of bladder
were made on whole fields at a screen magnification of
25×, relative densities were calculated in each 1.16 mm2
in area, and 4-5 mice were used per group. Values were
expressed as relative densities (%). To measure the size
of tumor and SLN, the mid-sectioned tissues were
stained with H&E. The stained tissues were photo-
graphed with a Zeiss microscope, surface areas of mid-
sectioned tumor and SLN were calculated using a Zeiss
Apotome microscope coupled to monochrome charge-
coupled device (CCD) camera and image analysis soft-
ware (AxioVision, Zeiss).
Enrichment of CD11b+ cells from OUBC by FACS and
RT-PCR
Single cell suspensions of OUBC were made by incuba-
tion with collagenase type IV (Worthington Biochemical
Corporation, Lakewood, NJ) for 1 hr, and the suspended
cells were washed with FACS buffer (Hank’s Buffered
Salt Solution (HBSS) + 4% bovine serum). The cells
were incubated for 15 min with rat monoclonal PE-
conjugated anti-mouse CD11b antibody 1:250 (BD Phar-
mingen). Dead cells were excluded by staining with
7-amino-actinomycin D (7-AAD, Invitrogen, Carlsbad,
CA). CD11b+ cells and CD11b- cells were enriched by a
FACS Aria II (BD Biosciences) according to the manu-
facturer’s instructions. The purities of subpopulations of
the enriched CD11b+ cells and CD11b- were ~98%
according to the FACS analysis. Total RNA from the
enriched CD11b+ cells and the CD11b- cells and normal
bladder were extracted using Trizol (Invitrogen) and
Qiagen RNeasy micro kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. Each
cDNA was made with Superscript II reverse transcrip-
tion system (Invitrogen). Quantitative RT-PCR was per-
formed with the Prime Q-Mastermix (Genet bio,
Chungnam, Korea) using the CFX96™ Real-time PCR
system (Bio-Rad, Hercules, CA). PCR reactions were
performed with the appropriate primers (Table 1) for 60
cycles.
Administration of blocking or depletion agent
To block VEGF-C/D, the mice were treated with tail
vein injections of 1.0 × 109 plaque-forming units (pfu)
of adenovirus encoding soluble VEGFR-3 (Ade-sVR3)
[25,26] twice on the day and two weeks after the MBT-
2 implantation. For systemic depletion of CD11b+/CD68
+ TAM, the mice were treated with intraperitoneal
injections of clodronate liposome (CDL, 25 mg/kg every
3 days i.p.) as previously described at 2 weeks after the
tumor implantation [22]. As a negative control, empty
control liposome (CL) was injected in the same manner.
Table 1 Primers for real-time RT-PCR
Genes Primer Sequences
VEGF-C Forward 5’-CGT TCT CTG CCA GCA ACA TTA CCA C-3’
Reverse 5’-CTT GTT GGG TCC ACA GAC ATC ATG G-3’
VEGF-D Forward 5’-GTC TGT AAA GCA CCA TGT CCG GGA G-3’
Reverse 5’-CCA CAG GCT GGC TTT CTA CTT GCA C-3’
HPRT Forward 5’-CCT CAT GGA CTG ATT ATG GAC A-3’
Reverse 5’-ATG TAA TCC AGC AGG TCA GCA A-3’
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Statistical analysis
Values presented are means ± standard deviation (SD).
Significant differences between means were determined
by Student’s t-test or analysis of variance followed by
the Student-Newman-Keuls test. The accepted level of
statistical significance was p < 0.05.
Results
OUBC presents profound lymphangiogenesis,
angiogenesis and TAM infiltration in tumor mass
Four weeks after the intravesical injection of MBT-2
cells, the lumen of urinary bladder was filled 70-80%
with the primary tumor mass (n = 12) (Figure 1A
upper). In H&E staining, the tumor invaded the mucosa,
submucosa, and muscle layer of bladder wall, which
means that OUBC is an invasive bladder tumor model,
and not a superficial bladder tumor (Figure 1A lower,
Additional File 1). Lymphatic and blood vessels were
identified by immunofluorescence staining for LYVE-1
(specific marker for lymphatic endothelial cells) and
PECAM-1 (specific marker for blood endothelial cells)
in sectioned samples of OUBC and control mice. Lym-
phatic and blood vessels in OUBC were robust and tor-
tuous, and were densely compacted (Figure 1B). The
overall number and size of the lymphatic vessels in the
bladder wall were increased in OUBC compared to the
control (Figure 1C), and the density of those vessels was
~3.0-fold higher in OUBC as well (Figure 1D). CD11b+,
CD68+ or F4/80+ TAM was largely infiltrated around
lymphatic vessels of tumor mass (Figure 1E). In the
CD11b+ TAM, 93 ± 5% (n = 5) was CD68+ and 72 ±
6% (n = 5) was F4/80+ cell (Additional File 2). Thus,
Figure 1 OUBC presents profound lymphangiogenesis, angiogenesis and CD11b+/CD68+ TAM infiltration. PBS (Control) or 1 × 106 MBT-2
cells (OUBC) were injected into the urinary bladders of 8-10-week old female C3H mice. 4 weeks after PBS or the tumor cell injection, the
bladders were harvested and stained. (A) Photos and images showing gross features and sections (H&E stained) of bladders. Scale bars, 2 mm.
(B) Images showing LYVE-1+ lymphatic vessels (LV) and PECAM-1+ blood vessels (BV). Scale bars, 100 μm. (C) Comparison of LV numbers at
different sizes of LV in the bladder sections. Graph shows mean ± SD; n = 5 for each group. *p < 0.05 versus Control. (D) Comparison of blood
vessel densities (BVD) per total sectioned area (0.84 mm2) of bladder. Graph shows mean ± SD; n = 5 for each group. *p < 0.05 versus Control.
(E) Images showing CD11b+, CD68+ and F4/80+ TAM infiltrated near LYVE-1+ lymphatic vessels in OUBC. Scale bars, 100 μm.
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TAM adjacent to lymphatic vessels in OUBC was
mainly CD11b+/CD68+/F4/80+/LYVE-1- cell.
OUBC displays marked lymphatic enlargement and
increased number of blood vessels in the peritoneal
surface of bladder wall
To examine changes in lymphatic and blood vessels in the
peritoneal surface of bladder, the samples were whole
mounted and immunostained for LYVE-1 or PECAM-1.
Compared to the control, lymphatic vessels on the perito-
neal surface were largely and variably enlarged, and
the number of blood vessels was higher in the OUBC
(Figure 2A). The densities of lymphatic and blood vessels
were 2.6- and 3.5-fold higher, respectively in the OUBC
(n = 5) than the control (n = 4) (Figure 2B).
OUBC showed lymphatic metastasis of cancer cells to
medial iliac lymph node
To examine the lymphatic spread of OUBC-derived cancer
cells to the lymph node, we harvested the medial iliac
lymph node that lies just above the aortic bifurcation site
(Figure 3A) as SLN at 4 weeks after the MBT-2 cell injec-
tion. In the OUBC, sizes of SLNs were substantially larger
(~3.8 fold) than those of control mice, and the structures
were significantly disorganized (Figure 3B, C, and 3D).
The densities of the lymphatic vessels in the medial iliac
lymph nodes in the OUBC were ~2.3 fold higher than
those of the control, whereas the densities of the blood
vessels in SLN did not differ significantly from those of
the control mice (Figure 3E left and 3F). To search for
metastatic tumor cells out in SLN, sections of the lymph
node were immunofluorescence stained with pan-cytoker-
atin, which is a useful marker for detecting of majority of
epithelial-origin carcinomas [27,28]. There were many
pan-cytokeratin stained cells in the medial iliac lymph
nodes of all OUBC mice (Density: 7.0 ± 1.3%, n = 5), while
there were no pan-cytokeratin stained cells in the lymph
node of control mice (n = 4) (Figure 3E right and 3G).
Higher magnification image revealed that metastatic
tumor cells congregated closely around lymphatic vessels
in the SLN (Figure 3E lower right), indicating that the
OUBC induces profound lymphatic metastasis of tumor
cells from the primary tumor mass to the SLN.
VEGFR-3 expressing CD11b+ TAM is the source of VEGF-C/D
The result of quantitative reverse transcription-polymerase
chain reaction (qRT-PCR) assay revealed that expression
levels of VEGF-C/D in bladder tumor mass are much
higher than those of normal bladder by 258.3 times and
321.0 times, respectively. To investigate the source and
Figure 2 OUBC displays markedly increased number of lymphatic and blood vessels in the peritoneal surface of bladder wall. PBS
(Control) or 1 × 106 MBT-2 cells (OUBC) were injected into the urinary bladders of 8-10-week old female C3H mice. 4 weeks after PBS or the
tumor cell injection, bladder was whole-mounted and immunostained for LYVE-1 and PECAM-1. (A) LYVE-1+ LVs and PECAM-1+ BVs in bladder
surface were visualized with DAB staining (brown). Scale bars, 200 μm. Arrows indicate profound and tortuous lymphangiogenesis and
arrowheads indicate robust increase of BV networks. (B) Comparison of lymphatic vessel densities (LVD) and BVD per total area (1.16 mm2) of
bladder. Graph shows mean ± SD; n = 5 for each group.*p < 0.05 versus Control.
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expression of VEGF-C/D that drive OUBC-induced lym-
phangiogenesis, we performed a series of qRT-PCR assays
in the CD11b+ TAM enriched by fluorescent activated cell
sorter (FACS) from OUBC (Figure 4A). qRT-PCR analysis
revealed that enriched CD11b+ TAM expressed higher
amount of VEGF-C (3.3-fold) and VEGF-D (2.0-fold)
when compared to the CD11b- cells in bladder tumor
mass (Figure 4B). Co-immunostaining analysis showed
that CD11b+ or CD68+ TAM expressed VEGF-C (Figure
4C upper). Moreover, VEGFR-3 was highly expressed not
only in the lymphatic vessels but also in the CD11b+ or
CD68+ TAM of the OUBC (Figure 4C lower).
Blockade of VEGF-C/D by soluble extracellular domain of
VEGFR-3 suppressed OUBC-induced lymphangiogenesis
and lymphatic metastasis to SLN but not CD11b+ TAM
recruitment
To investigate the effects of VEGF-C/D in the OUBC,
soluble extracellular domain of VEGFR-3 (sVR3) was
overexpressed by systemic adenoviral delivery (hereafter
referred as ‘Ade-sVR3’) [29] (n = 5). As a control, same
amount of Ade-bgal was treated in the same manner (n
= 4). At four weeks after the cancer cell implantation,
the number of the lymphatic vessels in tumor treated
with Ade-sVR3 showed significant decrease of 65% over
that of Ade-bgal-treated tumor (Figure 5B and 5D).
However, there were no significant changes in the
growth of tumor sizes and the densities of blood vessels
between the Ade-sVR3 versus the Ade-bgal (Figure 5A,
B,C and 5E). It was noted that blockade of VEGF-C/D-
VEGFR3 signaling is effective in disrupting lymphangio-
genesis in bladder tumor. Furthermore, distribution
densities of CD11b+ TAM in OUBC were indistinguish-
able between Ade-sVR3 and Ade-bgal, suggesting that
VEGF-C/D signaling has no effect on the recruitment of
CD11b+ TAM into the OUBC (Figure 5F). In SLN, the
Ade-sVR3 significantly decreased densities of lymphatic
vessels, but not blood vessels (Figure 5G and 5H).
Figure 3 OUBC displays profound increases in sizes of SLN and metastatic spread of cancer cells to SLN. PBS (Control, Co) or 1 × 106
MBT-2 cells (OUBC, Ob) were injected into the urinary bladders of 8-10-week old female C3H mice. 4 weeks after PBS or tumor cell injection,
medial iliac lymph nodes (LN) (arrows, A) were harvested as SLN, and photographed (B), and H&E stained (C, scale bars, 100 μm). (D)
Comparison of cross-sectional areas of LNs. Graph shows mean ± SD; n = 5 for each group. *p < 0.05 versus Co. (E) Images showing LYVE-1+
LVs, PECAM-1+ BVs, and cytokeratin+ (CytoK+) metastatic cancer cells in LNs. Right panel; high magnification view showing that the CytoK+
metastatic cancer cells congregate closely to the lymph node lymphatic vessels of OUBC. Scale bars, 50 μm. (F) Comparison of LVD and BVD per
total sectioned area of LNs. Graph shows mean ± SD; n = 5 for each group. *p < 0.05 versus Co. (G) Comparison of densities of CytoK+
metastatic cancer cells in LNs. Graph shows mean ± SD; n = 5 for each group. *p < 0.05 versus Co.
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Importantly, metastatic cancer cells in SLN were
decreased by 60% in the Ade-sVR3 compared to the
Ade-bgal (Figure 5I), indicating that blockade of VEGF-
C/D by Ad-sVR3 strongly suppressed lymphatic metas-
tasis to SLN.
CD11b+ TAM plays a crucial role in OUBC-induced
lymphangiogenesis
To clarify the role of infiltrating CD11b+ TAM in the
OUBC-induced lymphangiogenesis and angiogenesis, we
depleted macrophages, including CD11b+ TAM, sys-
temically by using the treatment of clodronate liposome
(CDL) [30,31] (n = 5). As a control, control liposome
(CL) was treated in the same manner (n = 4). Two
weeks after the CDL treatment, more than 90% of
CD11b+/CD68+ TAM were depleted in the tumor
region of the OUBC, whereas the CL treatment did not
affect the number of CD11b+/CD68+ TAM in the tumor
(Additional File 3). Although tumor sizes were indistin-
guishable between CDL treatment versus the CL treat-
ment (Figure 6A and 6C), the CDL treatment decreased
the number of lymphatic vessels in bladder tumor by
74% (Figure 6B and 6D). The CDL treatment also
showed the tendency to decrease blood vessel densities,
but it was not statistically significant (Figure 6B and 6E).
These data suggest that CD11b+ TAM plays a critical
role in inducing lymphangiogenesis in the OUBC.
Lymphatic metastasis of the OUBC was strongly inhibited
by depletion of CD11b+ TAM
To elucidate the role of CD11b+ TAM in lymphatic
metastasis in the OUBC, the SLN of CDL and CL trea-
ted mice were examined. Treatment with CDL, but not
CL, reduced the growth of lymphatic and blood vessels
in the SLN (Figure 6F left). The densities of lymphatic
and blood vessels in the SLN were decreased by about
Figure 4 CD11b+ or CD68+ TAM abundantly express VEGF-C/D and VEGFR-3. 1 × 106 MBT-2 cells were injected into the urinary bladders of
8-10-week old female C3H mice. 4 weeks after the tumor cell injection, single cell suspension of OUBC was prepared. (A) CD11b+ cells and
CD11b- cells were enriched by FACS with ~95% purity. (B) Comparison of mRNA expressions of VEGF-C/D in CD11b+ cells. Data are presented as
relative fold to CD11b- cells after standardization with hypoxanthine-guanine phosphoribosyl transferase (HPRT). Graph shows mean ± SD; n = 3
for each group. *p < 0.05 versus CD11b- cells. (C) Images showing CD11b+ or CD68+ TAM and VEGF-C+ or VEGFR-3+ cells in the sectioned
samples. Scale bars, 50 μm.
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30% and 40% in the CDL treatment compared to the CL
treatment, respectively (Figure 6G). The lymphatic
metastasis to the SLN was remarkably decreased by 70%
in the CDL treated group when compared to the CL
treated control group (Figure 6F right and 6H), indicat-
ing that CD11b+ TAM play crucial role in lymphatic
metastasis of bladder cancer cells.
Discussion
To establish distant metastasis, bladder tumor cells
spread from the bladder to target organs through three
main routes: hematogenous spread, lymphatic spread,
and direct seeding. In bladder cancer, lymph node was
known as the most common site of metastasis. Nearly
70% of bladder cancer patients experience lymphatic
metastasis in the course of disease progression [2]; thus,
lymph node metastasis is an important initial step
toward distant metastasis [32].
In present study, OUBC model was an invasive bladder
cancer which invades all layers of bladder wall and
displayed profound lymphangiogenesis in primary tumor
mass and SLN. Because TAM is known to play an impor-
tant role in tumor lymphangiogenesis by secreting
lymphangiogenic growth factor in other type of cancers
Figure 5 Blockade of VEGF-C/D-VEGFR-3 signaling suppresses profound lymphangiogenesis and lymphatic metastasis, but not
recruitment of CD11b+/CD68+ TAM. 1 × 106 MBT-2 cells were injected into the urinary bladders of 8-10-week old female C3H mice. At the
day of and two weeks after the tumor cell injection, 1 × 109 pfu Ade-bgal or Ade-sVR3 were injected intravenously to the OUBC mice. 4 weeks
after the tumor cell injection, the bladder and the SLN were sampled. (A) Images showing H&E stained sections of tumors. Scale bars, 2 mm. (B)
Comparison of cross-sectional area of tumors. Graph shows mean ± SD; n = 5 for each group. (C) Images showing LYVE-1+ LVs and PECAM-1+
BVs in tumors. Scale bars, 200 μm. (D) Comparison of LV numbers at different sizes of LV in the tumor sections. Graph shows mean ± SD; n = 5
for each group. *p < 0.05 versus Ade-bgal. (E) Comparison of BVD per total sectioned area of tumors. Graph shows mean ± SD; n = 5 for each
group. (F) Images showing CD11b+ TAM and LYVE-1+ cells. Scale bars, 200 μm. (G) Left panel; images showing LYVE-1+ LVs and PECAM-1+
BVs in LNs. Right panel; images showing LYVE-1+ LVs and CytoK+ metastatic cancer cells in LNs. Scale bars, 500 μm. (H) Comparison of LVD and
BVD in LNs. Graph shows mean ± SD; n = 5 for each group. *p < 0.05 versus Ade-bgal. (I) Comparison of densities of CytoK+ metastatic cancer
cells in LNs. Graph shows mean ± SD; n = 5 for each group. *p < 0.05 versus Ade-bgal.
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[20-22], we proposed that profound lymphangiogenesis is
associated with TAM, and bladder cancer cells can actively
metastasize through lymphatic vessels with the help of
TAM. In fact, one previous report indicates that TAM is
frequently observed in clinical samples of bladder cancer
[33], and that patients with high TAM count showed
higher frequencies of vascular invasion and distant metas-
tasis, and have lower 5-year survival rates than those with
low TAM count. Moreover, the TAM count and micro-
vessel densities were positively correlated to each other.
Indeed, the present study showed that there are massive
infiltration of CD11b+ macrophages located near the lym-
phatic vessels in primary tumor and SLN. Moreover,
immunofluorescence staining for the markers such as
CD68 and F4/80 revealed that most of TAM is the tumor
and metastasis-promoting M2-type [17].
The depletion of TAM by using CDL dramatically
decreased the lymphangiogenesis in tumor and SLN and
suppressed lymphatic metastasis of tumor cells to SLN,
indicating that TAM is an important pro-lymphangio-
genic and pro-metastatic modulator in the bladder
tumor. In addition to increasing the number of lympha-
tic vessels, TAM is able to condition the vessels to be
vulnerable to intravasation of tumor cells: TAM facili-
tates migration and intravasation of tumor cells by
secreting growth factors and chemotactic factors, and by
remodeling the extracellular matrix through collagen
fibril formation [34]. Therefore, in the present study, it
was possible that the anti-metastatic effect of CDL treat-
ment might have resulted from not only the suppression
of TAM-induced angiogenesis and lymphangiogenesis,
but also from the inhibition of TAM-induced tumor cell
migration and intravasation. However, contrary to pre-
vious report [31], depletion of TAM by CDL did not
significantly reduce the tumor mass in the bladder. This
could have resulted from the different characteristics of
Figure 6 Depletion of CD11b+/CD68+ TAM reduced OUBC-induced lymphangiogenesis and lymphatic spread of bladder cancer cells.
1 × 106 MBT-2 cells were injected into the urinary bladders of 8-10-week old female C3H mice. 2 weeks after the tumor cell injection,
clodronate liposome (CDL) or control liposome (CL) were injected intraperitonealy to the OUBC mice once every 3 days. 4 weeks after the tumor
cell injection, the bladder and SLN were sampled. (A) Images showing H&E stained sections of tumors. Scale bars, 2 mm. (B) Comparison of
cross-sectional area of tumors. Graph shows mean ± SD; n = 5 for each group. (C) Images showing LYVE-1+ LVs and PECAM-1+ BVs in tumors.
Scale bars, 200 μm. (D) Comparison of LV numbers at different sizes of LV in the tumor sections. Graph shows mean ± SD; n = 5 for each group.
*p < 0.05 versus CL. (E) Comparision of BVD per total sectioned area of tumors. Graph shows mean ± SD; n = 5 for each group. (F) Left panel;
images showing LYVE-1+ LVs and PECAM-1+ BVs in LNs. Right panel; images showing LYVE-1+ LVs and CytoK+ metastatic cancer cells in LNs.
Scale bars, 500 μm. (G) Comparison of LVD and BVD in LNs. Graph shows mean ± SD; n = 5 for each group. (I) Comparison of densities of CytoK
+ metastatic cancer cells in LNs. Graph shows mean ± SD; n = 5 for each group. *p < 0.05 versus CL.
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tumors in growing different organs. This orthotopic
tumor grows mainly into the bladder cavity without
invading its supporting tissues, a growth pattern that is
quite different from that of other solid tumors.
Interestingly, CD11b+/CD68+ TAM expresses higher
levels of VEGF-C/D than CD11b- cells, which were also
known as the main mediator of tumor-associated lym-
phangiogenesis and lymphatic metastasis. Because
CD11b+/CD68+ TAM flocked near the lymphatic vessels
and VEGFR-3 was highly expressed in the lymphatic vas-
cular endothelial cells, TAM could assist tumor-induced
lymphangiogenesis by paracrine secretion of VEGF-C/D
in bladder cancer. Moreover, co-immunostaining results
showed that VEGFR-3 is also highly expressed in the
CD11b+ TAM in itself, indicating that TAM may have
autocrine and paracrine positive feedback loop to boost
further secretion of VEGF-C/D. Consequently, once
TAM is activated to become M2-type, it could accelerate
lymphangiogenesis and lymphatic metastasis by the para-
crine and autocrine mechanism. From this study, we
could not exclude the partial contribution of tumor cells
to the source of VEGF-C/D. Nevertheless, we were able
to exclude the idea that tumor cells are the main source
of tumor lymphangiogenesis, because depletion of
macrophages by the CDL treatment caused >80% reduc-
tion in VEGF-C/D expressions in the tumor mass com-
pared to the control CL treatment.
In addition, present data also indicate that the sup-
pression of VEGF-C/D signaling by adenoviral delivery
of sVR3 significantly reduced the growth of lymphatic
vessels in bladder tumor and SLN and eventually inhib-
ited lymphatic metastasis of bladder tumor cells from
primary tumor to SLN without significant reductions of
tumor mass and blood vessels in OUBC. These findings
are mostly consistent with previously reported findings
in the different tumor models [11-13]. Therefore, we
postulated that lymphatic spread of cancer metastasis in
patients with bladder cancer can be prevented by speci-
fic suppression of VEGF-C/D-VEGFR3 signaling path-
ways. But, this strategy seemed to have a limitation
when reducing preformed tumor burden. In other
words, because blocking lymphangiogenesis is rather
tumoristatic than tumoricidal, blocking VEGF-C/D
might be particularly useful when tumor burden is mini-
mal, for example in the postoperative adjuvant setting.
In comparison, recent studies [35,36] show that VEGFR-
3 is upregulated in the tumor vasculature; also, loss-of-
function studies by genetic targeting of VEGFR-3 or
blocking of its signaling with monoclonal antibodies
resulted in decreased sprouting, indicating that VEGFR-
3 has a role in angiogenic sprouting formation. The dis-
crepancies in responsiveness to VEGFR-3 blocking
experiments could have resulted from the different
expression level of VEGFR-3 in the tumor vasculatures
in varying tumor models. Indeed, the vasculatures and
the sizes of our bladder cancer models are not respon-
sive to the soluble VEGFR-3 treatment, which might be
due to the low expression of VEGFR-3 in the tumor
vasculatures.
Until now, even after successful radical cystectomy
and lymph node dissection, about 50% of bladder cancer
patients eventually show recurrence and have poor sur-
vival [1]. For more than 30 years, there have been many
efforts to reduce the recurrence of high-risk bladder
cancer after curative surgery, however, numerous clini-
cal trials failed to show conclusive evidence on the
impact of adjuvant chemotherapy even by using the
most toxic combination regimens [37]. Considering
these facts, blocking VEGF-C/D pathway and lymphan-
giogenesis could be another attractive alternative to
reduce the recurrence of bladder tumor after curative
radical cystectomy.
Conclusion
In summary, a profound OUBC-induced lymphangiogen-
esis in primary cancer and SLN contribute to lymphatic
metastasis by VEGF-C/D and VEGFR-3 signaling. Infil-
trated CD11b+/CD68+ TAM is intensely involved in
OUBC-induced lymphangiogenesis and lymphatic metas-
tasis and therefore TAM could be the bridge between
primary cancer and SLN. Our study, which shows the
therapeutic inhibition of lymphangiogenesis, provides
another therapeutic target to inhibit lymphatic metastasis
and recurrence in patients with invasive bladder cancer.
Additional material
Additional file 1: OUBC is a muscle-invasive bladder cancer. PBS
(Control) or 1 × 106 of MBT-2 cells (OUBC) were injected into the urinary
bladder of 8-10-week old female C3H mice. 4 weeks after PBS or tumor
cell injection, the bladders were harvested and stained with H&E. Images
showing sectioned bladders. Arrows indicate the tumor cells which
invaded the muscle layer.
Additional file 2: Most TAM in OUBC are CD11b+/CD68+/F4/80+
cells. 1 × 106 of MBT-2 cells were injected into the urinary bladder of 8-
10-week old female C3H mice. 4 weeks after tumor cell injection, the
bladders were harvested and stained. Images showing CD11b+, CD68+
and F4/80+ TAM in tumors. Scale bars, 100 μm.
Additional file 3: Depletion of TAM by CDL in OUBC. 1 × 106 of MBT-
2 cells were injected into the urinary bladder of 8-10 week old female
C3H mice. 2 weeks after tumor cell injection, CDL or CL was
intraperitonealy injected to the mice bearing OUBC at every 3 day. 4
weeks after tumor cell injection, the bladders were harvested and
immunostained. (A) Images showing CD11b+/CD68+ TAM in the CL or
CDL treated mice. Scale bars, 100 μm. (B) High magnification view
showing the depletion of CD11b+ TAM in CDL treated mice compared
to CL treated mice. Scale bars, 100 μm.
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